Related Experiment Video

Updated: Aug 18, 2026

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
06:35

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis

Published on: February 8, 2019

Poor prognosis of visual outcome after visual loss from giant cell arteritis

Helen Danesh-Meyer1, Peter J Savino, Greg G Gamble

  • 1Department of Ophthalmology, University of Auckland, Auckland, New Zealand.

Ophthalmology
|May 12, 2005
PubMed

Insights

Visual recovery is rare for patients experiencing vision loss from giant cell arteritis (GCA), even with high-dose corticosteroids. Vision deterioration can occur early, with little improvement in visual fields or color vision.

Area of Science:

  • Ophthalmology
  • Rheumatology
  • Neuro-ophthalmology

Background:

  • Giant cell arteritis (GCA) is a systemic vasculitis that can lead to irreversible vision loss.
  • Early diagnosis and treatment are crucial to prevent severe complications, including blindness.

Purpose of the Study:

  • To determine the incidence and extent of visual recovery in patients with GCA who experienced vision loss.
  • To assess the impact of high-dose systemic corticosteroid treatment on visual outcomes in GCA patients.

Main Methods:

  • A multicenter prospective case series involving 34 patients with biopsy-proven GCA and visual loss.
  • Comprehensive neuro-ophthalmic evaluations, including visual acuity, visual fields, and color vision testing.
  • Treatment with high-dose intravenous methylprednisolone followed by oral prednisone, with regular monitoring and dose adjustments.

Main Results:

  • Patients presented with a mean visual acuity of 20/400.
  • Visual deterioration occurred in 27% of affected eyes within the first week, despite high-dose IV corticosteroids.
  • Only 15% of eyes showed improved visual acuity within the first month, with a mere 5% demonstrating concurrent visual field improvement.

Conclusions:

  • Visual recovery is uncommon in GCA patients with established vision loss.
  • Improvements in visual acuity do not consistently correlate with improvements in visual field or color vision.
  • A significant risk of visual deterioration exists within the first week of treatment, even with aggressive corticosteroid therapy.
Abstract

Related Concept Videos

Glaucoma: Overview01:25

Glaucoma: Overview

Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
Diabetic Retinopathy01:27

Diabetic Retinopathy

DefinitionDiabetic retinopathy is a microvascular complication of diabetes affecting the retinal blood vessels.Risk FactorsDiabetic retinopathy is present in almost all individuals with type 1 diabetes and more than 60% of those with type 2 diabetes after two decades of disease.The risk increases with poor glycemic control, hypertension, dyslipidemia, smoking, pregnancy, and puberty.Although cataracts and glaucoma are also more frequent in people with diabetes, retinopathy remains the leading...
Photoreceptors and Visual Pathways01:22

Photoreceptors and Visual Pathways

At the molecular level, visual signals trigger transformations in photopigment molecules, resulting in changes in the photoreceptor cell's membrane potential. The photon's energy level is denoted by its wavelength, with each specific wavelength of visible light associated with a distinct color. The spectral range of visible light, classified as electromagnetic radiation, spans from 380 to 720 nm. Electromagnetic radiation wavelengths exceeding 720 nm fall under the infrared category, whereas...
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...